← Back to Search

Optical coherence tomography confirmed residual thrombus for Basilar Artery Stroke

N/A
Waitlist Available
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- All patients deemed candidates for endovascular thrombectomy(EVT) for basilar artery occlusion. As no robust guidelines exist for the role of EVT in patients with acute basilar artery occlusion, the decision for EVT is made by a team of stroke neurologist and neuro-interventionalist at our regional stroke center.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

Study Summary

This trial will test whether or not it is safe to give antithrombotics to people who have had a stroke and have had their thrombus removed.

Eligible Conditions
  • Basilar Artery Stroke
  • Optical Coherence Tomography
  • Anticoagulants
  • Endovascular Thrombectomy

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours ct imaging ± 8 hours.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours ct imaging ± 8 hours. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Favorable outcome
Secondary outcome measures
Excellent Outcome
Incidence of residual thrombus
Symptomatic Intracranial Hemorrhage

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Optical coherence tomography confirmed residual thrombusExperimental Treatment2 Interventions
Early antithrombotics
Group II: Optical coherence tomography confirmed no residual thrombusActive Control1 Intervention
Best medical management
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetylsalicylic acid
FDA approved
Heparin
FDA approved

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
656 Previous Clinical Trials
1,550,597 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
StrokeJournal
2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/american Stroke Association
Powers, William J., Alejandro A. Rabinstein, Teri Ackerson, Opeolu M. Adeoye, Nicholas C. Bambakidis, Kyra Becker, José Biller, et al.. 2018. “2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/american Stroke Association”. Stroke. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/str.0000000000000158.
clinicaltrials.govStudy
Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation
Dr. Victor Yang 2019. "Optical Coherence Tomography Guided Antithrombotic Treatment After Endovascular Thrombectomy of the Posterior Circulation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04121611.
All > Durlaza
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top